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Once cutaneous melanoma metastasizes prognosis of patients is generally poor in spite of recent 
therapeutic advances. Prognostic biomarkers are needed to better identify those patients with 
primary melanoma who are at increased risk of metastatic disease. Gene expression signatures 
have been defined that are associated with metastatic capacity of primary melanoma and survival 
(Winnepenninckx et al., 2006; Conway et al., 2009). Genomic characterization has revealed 
diverse recurrent genetic alterations including those that drive the tumorigenic process. However, 
the underlying molecular changes that confer the capacity to melanoma cells to migrate and 
colonize distant body sites remain to be defined. Promoter CpG island hypermethylation 
constitutes a mechanism responsible for deregulated expression of genes involved in metastasis. 
We and others have identified epigenetic alterations in melanoma affecting genes with a potential 
role in tumour cell dissemination including CDH11 and SERPINB5 (Carmona et al., 2012; Dahl 
et al., 2015; Gao et al., 2013). Additionally a 17-gene methylation signature was found to predict 
disease course of stage IIIC melanoma patients (Sigalotti et al., 2012). As epigenetic biomarker 
for metastasis, promoter hypermethylation has the advantage that it is stable and can be reliably 
detected in clinical samples. The purpose of this study was to identify methylation events that can 
predict development of lethal metastatic disease in patients with primary cutaneous melanoma. 
To this end, we collected clinical follow-up data of 24 patients with primary melanoma 
whose tumours had been previously subjected to genome-wide DNA methylation profiling using 
Illumina 27K arrays, analyzing methylation of 14,495 genes (Gao et al., 2013). Thirteen patients 
had developed distant metastases, all of whom died due to melanoma, and in 11 patients no 
metastatic dissemination or tumour recurrence had been detected during a follow-up period of at 
least six years after diagnosis. We compared methylation profiles from primary melanomas of 
patients who developed lethal distant organ metastasis (M+) to those from primary melanomas of 
patients who had not developed metastasis (M-). CpG probes with an average ȕ-value difference 
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(a measure of differential DNA methylation reflecting fluorescence intensity ratios between 
methylated and unmethylated alleles) higher than 0.20 between M+ and M- primary melanomas 
were considered indicative of hypermethylation of the corresponding gene promoter region. This 
re-analysis yielded six candidate hypermethylated genes in melanoma with metastatic behavior 
(M+): MCHR1, SYNPO2, C1orf106, HIST1H3G, ZNF35, and GNMT (Figure 1a). We did not 
find genes hypomethylated in melanoma with metastatic behavior. Validation of these six genes 
in an independent series of 20 fresh-frozen M+ primary melanomas and 25 M- primary 
melanomas using bisulphite melting curve analysis (BMCA) showed promoter hypermethylation 
of MCHR1 and SYNPO2 to be associated with metastatic behavior (Supplementary Table S1). 
We proceeded with promoter methylation analysis of MCHR1 and SYNPO2 in an independent 
series of 113 formalin-fixed paraffin-embedded (FFPE) primary invasive cutaneous melanoma 
samples with available melanoma-specific survival data using methylation-specific PCR 
(Supplementary Table S2a-c and Supplementary Materials and Methods). This demonstrated for 
the MCHR1 promoter a gradual, but not absolute methylation difference between metastatic and 
non-metastatic melanoma samples, limiting its use as prognostic biomarker. There was a marked 
difference in SYNPO2 promoter methylation between metastatic and non-metastatic melanomas 
(Figure 1b). Primary melanomas with SYNPO2 promoter hypermethylation had a significantly 
shorter survival (hazards ratio for melanoma-related death 2.01, 95% confidence interval 1.06-
3.82; P<0.034 in univariate analysis) (Figure 2a). Importantly, SYNPO2 promoter 
hypermethylation remained a statistically significant prognostic factor after adjusting for tumour 
thickness (hazards ratio for melanoma-related death 2.02, 95% confidence interval 1.05-3.89, 
P<0.034 in multivariate analysis) (Supplementary Table S3). When considering tumour 
thickness, age (as continuous variables), gender and ulceration as covariates in multivariate 
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analysis, still an association of SYNPO2 methylation and reduced melanoma-specific survival 
was observed that did not reach statistical significance in this sample series.   
SYNPO2 promoter methylation was shown to associate with transcriptional repression 
(Cebrian et al., 2008). Demethylation using 5-aza-ƍ-deoxycytidine of three SYNPO2-methylated 
melanoma cell lines resulted in reactivation of expression in treated cells, providing evidence for 
a link between promoter methylation and transcription regulation in melanoma (Figure 2b, 
Supplementary Figure S1). To examine if SYNPO2 gene expression levels provided prognostic 
information and to support a role for epigenetic silencing of this gene in acquisition of metastatic 
behaviour, we investigated its expression in 202 primary melanomas from the Leeds Melanoma 
cohort and tested correlation with melanoma-specific survival (Supplementary Table S2d) 
(Conway et al., 2009; Jewell et al., 2015). Illumina DASL HT12 v4 arrays were used to measure 
whole genome gene expression in FFPE tumours and after quantile normalisation melanoma-
specific survival analysis was conducted (Supplementary Materials and Methods). Two SYNPO2 
probes were available on the DASL array (ILMN_1688220 and ILMN_1730218). The 
association of low expression with shorter melanoma-specific survival was statistically 
significant for ILMN_1688220 before and after adjusting for age, gender and tumour thickness in 
Cox proportional hazards regression (hazards ratio for melanoma-related death 2.04, 95% 
confidence interval 1.08-3.85, P<0.04) (Figure 2c, Supplementary Table S4). The 
ILMN_1730218 probe showed a similar trend in association with melanoma-specific survival 
although it did not reach statistical significance after adjusting for these covariates 
(Supplementary Table S4). The gene expression data are therefore consistent with an association 
between SYNPO2 silencing by promoter methylation and shorter survival. SYNPO2 has multiple 
isoforms, which may explain a weaker association found for one of the probes (De Ganck et al., 
2008). Summarizing, SYNPO2 hypermethylation and diminished expression are associated with 
© 2015 The Society for Investigative Dermatology
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shorter melanoma-specific survival. Prognostic significance of SYNPO2 hypermethylation and 
gene expression is independent of tumour thickness. 
In line with our observations in melanoma, SYNPO2 methylation was found to associate 
with tumor aggressiveness and poor clinical outcome in patients with bladder and colon cancer 
(Alvarez-Mugica et al., 2010; Esteban et al., 2012). In aggressive prostate cancer the locus on 
chromosome 4q26 harboring SYNPO2 is frequently deleted (Lin et al., 2001). SYNPO2 encodes 
myopodin, a member of synaptopodin family of actin-binding proteins that regulate cell shape 
and motility. In prostate cancer cells myopodin inhibits tumor growth and invasion in vitro and in 
vivo (Jing et al., 2004). The ability of myopodin to inhibit tumor cell migration depends on its 
binding to zyxin and integrin-link kinase (Yu and Luo, 2006; Yu and Luo, 2011). It is thought 
that myopodin primarily affects cell migration and invasion by inducing changes in actin 
cytoskeleton networks (Kai and Duncan, 2013). The potential involvement of myopodin in 
melanoma cell dissemination deserves further examination. The clinical value of SYNPO2 
methylation in predicting metastatic behaviour of primary melanoma should be addressed in 
larger prospective studies, possibly combined with other candidate epigenetic markers. 
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Figure 1. Differential promoter methylation in primary melanomas with different 
metastatic outcome. 
a. Methylation profiles of primary melanomas from patients who developed lethal distant organ 
metastasis (M+, n=13) were compared to those from patients who had not developed metastasis 
(M-, n=11), yielding six genes with average ȕ-value difference higher than 0.20. 
b. SYNPO2 amplification products from MSP are shown for two M- primary melanomas and 
three M+ primary melanomas. u, unmethylated; m, methylated; ctrl +, positive control 
(lymphocyte DNA treated with Sss1 methyltransferase); ctrl -, negative control (DNA from 
human umbilical vein endothelial cells); H2O(1), no template control for first amplification with 
flanking primers; H2O(2), no template control for second amplification with primers specific for 
methylated and unmethylated DNA. 
 
Figure 2. SYNPO2 promoter methylation and expression status are associated with survival 
outcome. 
a. Kaplan-Meier estimate of survival function for melanoma-related death by SYNPO2 promoter 
methylation status was calculated and plotted against TTDOLC (time until dead or last contact). 
Grey line, primary melanomas scored as negative for SYNPO2 promoter methylation using MSP; 
black line, primary melanomas scored as positive. P<0.05 from Log rank test was considered 
significant. 
b. Relative SYNPO2 mRNA expression in melanoma cell lines WM35, WM3248 and 530 treated 
ZLWKHLWKHUPRFNRUȝ0-aza-ƍ-deoxycytidine for 96 hours. Expression levels were analysed in 
duplicate. *P < 0.05; **P < 0.01. 
c. Kaplan-Meier estimate of survival function for melanoma-related death by probe 
ILMN_1688220 measuring SYNPO2 expression in 202 primary melanomas from the Leeds 
© 2015 The Society for Investigative Dermatology
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Melanoma cohort. Grey line, primary melanomas with high SYNPO2 expression; black line, 
primary melanomas with low SYNPO2 expression. P<0.05 from Log rank test was considered 
significant. 
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